PRPH Company Profile and Key Details

Q: Who are the executives of PRPH?

Mr. Jason KarkusPres of ProPhase DiagnosticsMr. Ted William KarkusChairman & Chief Executive OfficerMs. Monica BradyChief Accounting OfficerMr. Billy Joe WhiteConsultantMr. Sergio MirallesExecutive Vice President & Chief Information Officer of ProPhase DiagnosticsMr. Kamal ObbadSenior Vice President and Director of Sales & Marketing - Nebula GenomicsMr. Robert A. Morse Jr.Chief Financial Officer, Principal Financial Officer & Principal Accounting OfficerMr. Sam A. BeelerChief Strategy Officer of Nebula GenomicsMs. Alice LioiEVice President & Chief Operating Officer of ProPhase Diagnostics and ProPhase BioPharmaMr. Dennis GrishinChief Scientific Officer of Nebula Genomics

NASDAQ : PRPH

ProPhase Labs

$0.08

-0.015-16.67%

At Close 4:00 PM

72.48

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ProPhase Labs, Inc. (PRPH) stock remained unchanged at $0.09 a share on NASDAQ. The stock opened at $0.07, fluctuating between $0.07 to $0.09 during the session.

Stock Snapshot

0.09

Prev. Close

426.33K

Market Cap

0.0728

Day Low

N/A

P/E Ratio

-19.8

EPS (TTM)

-0.8

Cash Flow per Share

0.07

Open

4.74M

Number of Shares

0.09

Day High

92.01%

Free Float in %

2.74

Book Value

43.15K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 20, 2026	0.07	0.09	0.07	0.08	43.15K
Mar 19, 2026	0.09	0.09	0.07	0.07	142.97K
Mar 18, 2026	0.10	0.10	0.07	0.10	521.43K
Mar 17, 2026	0.12	0.13	0.09	0.09	635.86K
Mar 16, 2026	0.13	0.13	0.00	0.00	1.03M
Mar 13, 2026	0.15	0.15	0.00	0.00	111.93K
Mar 12, 2026	0.15	0.15	0.14	0.14	121.41K
Mar 11, 2026	0.15	0.15	0.13	0.15	6.47K
Mar 10, 2026	0.13	0.15	0.13	0.14	17.14K
Mar 09, 2026	0.11	0.15	0.11	0.13	22.08K
Mar 06, 2026	0.13	0.15	0.13	0.13	22.64K
Mar 03, 2026	0.13	0.15	0.13	0.15	42.69K
Mar 02, 2026	0.15	0.16	0.14	0.15	81.96K
Feb 27, 2026	0.16	0.16	0.15	0.15	39.99K
Feb 26, 2026	0.15	0.16	0.14	0.16	3.47K
Feb 25, 2026	0.15	0.16	0.15	0.15	166K
Feb 24, 2026	0.15	0.15	0.15	0.15	11.91K
Feb 23, 2026	0.15	0.15	0.15	0.15	3.44K
Feb 20, 2026	0.14	0.16	0.14	0.15	53.85K
Feb 19, 2026	0.17	0.18	0.15	0.16	120.9K

Contact Details

Garden City, NY 11530

United States

https://www.prophaselabs.com 215 345 0919

About Company

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 NBIX

-2.02-1.56%

Neurocrine Biosciences, Inc.$127.68 LNTH

-1.56-2.00%

Lantheus Holdings, Inc.$76.43 ANIP

-0.15-0.20%

ANI Pharmaceuticals, Inc.$74.67 PAHC

-1.62-3.09%

Phibro Animal Health Corporation$50.76 SUPN

-1.08-2.21%

Supernus Pharmaceuticals, Inc.$47.76 COLL

-0.86-2.37%

Collegium Pharmaceutical, Inc.$35.44 HROW

-1.13-3.28%

Harrow Health, Inc.$33.28 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 INDV

-1.2-3.93%

Indivior Pharmaceuticals Inc$29.30

Company Overview

The stock is currently mid-range between its 52-week high and low $0.07 and $6.70. With a market capitalization of about $426.33 thousand, ProPhase Labs, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.52). Key stats such as the average daily volume over the past year has been around 454.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Garden City, NY, ProPhase Labs, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Ted William Karkus, the company employs approximately 96 people and listed since April 04, 1994. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.

Technical Performance

PRPH has shown weak momentum, losing -56.64% over the past week and -99.65% over the past quarter, though year-to-date performance is down -56.4%. Short-term trend indicators are bullishly aligned (SMA20 -62.48%, SMA50 -82.11%, SMA200 -89.23%). The stock’s 14-day RSI is 18.45 (weak momentum), while the ATR of 0.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.12% below its high and over 20.87% above its low. Average 10-day trading volume of 414.56 thousand shares is slightly above the 3-month average of 324.49 thousand, indicating heightened recent market interest.

Valuation Metrics

ProPhase Labs, Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.4 and a price-to-book ratio of 0.05 suggesting the stock is closer to book value. The P/FCF stands at -0.02, also above market averages.

Dividend & Fair Value

ProPhase Labs, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.31. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

ProPhase Labs, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is -57.56%. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at $nan. Next year's EPS is expected at $48.63. ProPhase Labs, Inc. earnings surprise history is a mixed track record. The quarter that ended November 19, 2025, missed forecasts by 49.66%. The prior quarter beat by -26.67%. Over the last six quarters, Apple has recorded several small beats. These include 307.2% in August 14, 2024.

Shareholding & Insider Activity

ProPhase Labs, Inc. has 41.54 million shares outstanding. The public float is 38.22 million shares, elevated short interest at 6.82% of float. This equals 2.55 million shares. The short ratio is 0.19 days. Institutional investors hold 7.14% of the float. Insiders own 7.99%. Karkus Ted William holds 2.33 million shares, PHILLIPS CHARLES A has 1.01 million shares and Leventhal Mark S has 881.98 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, ProPhase Labs generated $44.38M in revenue, or $2.58 per share. Gross margin was 36.59%, operating margin -48.70%, and net profit margin -37.81%. Returns are negative, with ROA at -18.26% and ROE at -33.98%.
On valuation metrics, ProPhase Labs trades at a P/E of -0.01, P/S of 0.40 and P/B of 0.05. Liquidity is tight, with a current ratio of 0.14 and quick ratio of 0.14. Operationally, the company’s inventory turnover is -3.70 and cash conversion cycle is 16537.18 days. Debt-to-equity is 1.12, supported by a cash flow-to-debt ratio of -2.99.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ProPhase Labs posted revenue of $44.38M, down slightly from $122.65M in the prior quarter. Gross profit was $16.24M (margin 36.59%). Operating income was - $21.61M (margin -48.7%). Net income was- $16.78M (EPS - $0.98).
The company ended the quarter with $5.28M in cash and short-term investments, a total debt of $21.38M, and net debt of $19.23M. Total assets were $91.93M, with equity of $49.38M. Financials further reflected weakness, with operating cash flow of - $11.35M, free cash flow of - $14.50M, and capital expenditures of - $3.16M.

Price Forecast & Outlook

Our AI price prediction model suggests that ProPhase Labs, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -46.67%, with price expected at $0.04 by April 03, 2026, within a range of $0.01 to $0.08 3-Month Outlook: Projected fall of -86.67%, reaching $0.01 by June 18, 2026, with a range of $0.00 to $2.13. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 19, 2027, within a range of $0.00 to $3.99.

Key Takeaways

ProPhase Labs, Inc. (NASDAQ:PRPH) shares are down -56.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ProPhase Labs, Inc. trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.40, suggesting 20433.33% upside. Our AI forecast model points to short-term weakness (-46.67% over two weeks), a medium-term fall (-86.67% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ProPhase Labs, Inc. (PRPH) stock price?

ProPhase Labs, Inc. (NASDAQ: PRPH) stock price is $0.09 in the last trading session. During the trading session, PRPH stock reached the peak price of $0.09 while $0.07 was the lowest point it dropped to. The percentage change in PRPH stock occurred in the recent session was 0% while the dollar amount for the price change in PRPH stock was $0.00.

PRPH's industry and sector of operation?

The NASDAQ listed PRPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. ProPhase Labs, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRPH?

Mr. Jason Karkus
Pres of ProPhase Diagnostics
Mr. Ted William Karkus
Chairman & Chief Executive Officer
Ms. Monica Brady
Chief Accounting Officer
Mr. Billy Joe White
Consultant
Mr. Sergio Miralles
Executive Vice President & Chief Information Officer of ProPhase Diagnostics
Mr. Kamal Obbad
Senior Vice President and Director of Sales & Marketing - Nebula Genomics
Mr. Robert A. Morse Jr.
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Mr. Sam A. Beeler
Chief Strategy Officer of Nebula Genomics
Ms. Alice Lioi
EVice President & Chief Operating Officer of ProPhase Diagnostics and ProPhase BioPharma
Mr. Dennis Grishin
Chief Scientific Officer of Nebula Genomics

How PRPH did perform over past 52-week?

PRPH's closing price is 7.14% higher than its 52-week low of $0.07 where as its distance from 52-week high of $6.70 is -98.88%.

How many employees does PRPH have?

Number of PRPH employees currently stands at 96.

Link for PRPH official website?

Official Website of PRPH is: https://www.prophaselabs.com

How do I contact PRPH?

PRPH could be contacted at phone 215 345 0919 and can also be accessed through its website. PRPH operates from 711 Stewart Avenue, Garden City, NY 11530, United States.

How many shares of PRPH are traded daily?

PRPH stock volume for the day was 43.15K shares. The average number of PRPH shares traded daily for last 3 months was 454.59K.

What is the market cap of PRPH currently?

The market value of PRPH currently stands at $426.33K with its latest stock price at $0.09 and 4.74M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	96
Beta	-0.52
Sales or Revenue	$44.38M
5Y Sales Change%	1.239%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

PRPH Company Profile and Key Details

ProPhase Labs

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook